WannaCry ransomware may be authored by hackers from Southern China — mediaWorld May 29, 8:58
Russia’s Eastern Military District receives new shipment of Terminator helicoptersMilitary & Defense May 29, 8:18
North Korea test fires another missileWorld May 29, 1:29
Russia’s Zvyagintsev wins Jury Prize at 70th Cannes Film Festival with his LovelessSociety & Culture May 28, 21:32
Three Russian tourists hurt is road accident with tourist minibus in TurkeySociety & Culture May 28, 18:58
Some 40,000 cyclists taking part in Moscow cycle paradeSociety & Culture May 28, 18:33
Corporation Irkut: MS-21 first flight performed in routine modeBusiness & Economy May 28, 16:54
Ukrainian military launch more than 180 shells, mines on Donetsk within one dayWorld May 28, 16:36
Minister: Russia may supply 1,000 MC-21 planes to 2037Business & Economy May 28, 14:42
GENEVA, June 14. /TASS/. The Court of Arbitration for Sport announced on Tuesday that it would announce its decision regarding an appeal from Russian tennis player Maria Sharapova before July 18.
According to various media reports earlier in the day, tennis star Sharapova has filed an appeal with the CAS in Switzerland’s Lausanne against her two-year suspension, which was imposed last week by the International Tennis Federation’s (ITF) Tribunal over anti-doping violations.
"In her appeal to the CAS, Ms Sharapova seeks the annulment of the Tribunal’s decision to sanction her with a two-year period of ineligibility further to an anti-doping rule violation," the CAS said in its statement. "Ms Sharapova submits that the period of ineligibility should be eliminated, or in the alternative, reduced."
"The parties have agreed to an expedited procedure which will allow the CAS to render a decision, at the latest, on 18 July 2016," the statement added.
In early March, Sharapova announced that her doping tests revealed the presence of performance enhancing drug meldonium in the body system. Following the announcement, former World’s No. 1 was provisionally suspended from all tennis-related activities.
The drug meldonium (mildronate) was included in the list of preparations banned by WADA from January 1, 2016. The presence of the meldonium substance in the athlete’s blood during and between competitions is a violation of anti-doping rules. The substance belongs to S4 class on the WADA blacklist (hormones and metabolic modulators).
WADA announced on April 13 that the concentration of less than one microgram of meldonium in the body system of an athlete, whose doping tests were conducted before March 1, was acceptable.